Clinical trials
Phase 2 Neuroectodermal Tumors, Primitive, Peripheral trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2017 | 6 |
| 2018 | 4 |
| 2020 | 3 |
| 2021 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 38 |
| Active, not recruiting | 8 |
| Terminated | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 24 |
| Memorial Sloan Kettering Cancer Center | 8 |
| Children's Oncology Group | 6 |
| City of Hope Medical Center | 2 |
| Columbia University | 1 |
| Daiichi Sankyo | 1 |
| Dana-Farber Cancer Institute | 1 |
| Eastern Cooperative Oncology Group | 1 |
| Eli Lilly and Company | 1 |
| M.D. Anderson Cancer Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neuroectodermal Tumors, Primitive, Peripheral | 48 |
| Sarcoma | 38 |
| Osteosarcoma | 31 |
| Neuroblastoma | 25 |
| Rhabdomyosarcoma | 20 |
| Wilms Tumor | 18 |
| Medulloblastoma | 17 |
| Hepatoblastoma | 16 |
| Central Nervous System Neoplasms | 14 |
| Ependymoma | 14 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.